BioMS Medical Corp (TSX: MS), a leading
developer of products for the treatment of multiple sclerosis (MS), announced
that it has received regulatory approval to initiate a phase II human clinical
trial to investigate the efficacy and safety of MBP8298 in patients with
relapsing-remitting multiple sclerosis (RRMS) in the first of several European
countries. Patient enrollment is targeted to commence in the third quarter of
this year and BioMS anticipates up to 30 sites will participate.
